Business Wire

TX-MARY-KAY-INC.

Share
Mary Kay Inc. Highlights Ocean Action and Partnership With The Nature Conservancy on Earth Day 2022

This Earth Day marks the 52nd anniversary of the first Earth Day celebrated in 1970. Mary Kay Inc. joins in celebrating the environment and all of the partnerships around the world working to invest in our planet and achieve the United Nations (UN) 17 Sustainable Development Goals (SDGs) .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220422005430/en/

A key component of tackling climate change and achieving the SDGs is dependent on ocean action. The ocean covers 70 percent of the Earth’s surface, is the planet's largest biosphere, and is home to up to 80 percent of all life in the world. It generates 50 percent of the oxygen we need, absorbs 25 percent of all carbon dioxide emissions and captures 90 percent of the additional heat generated from those emissions.1

The Nature Conservancy (TNC) has embarked on a journey to protect our oceans, with support from Mary Kay, which holds water at the heart of its sustainability strategy: “This Earth Day, our oceans need us all,” said Jeffrey Parrish, Global Managing Director for Nature Protection at The Nature Conservancy. “With support from our corporate partners, TNC is working every day across the globe to conserve the reefs, coasts and fisheries that make life on this Planet, and our own lives, thrive. Together, we are making every day Earth Day.”

Through the collective partnership, Mary Kay supports projects resulting in sustainable impact preserving and protecting our oceans:

  • Global ocean protection to improve ocean health for nature and people;
  • Protecting climate-resilient coral reefs, “super reefs,” in the Coral Triangle;
  • Restoring Asia Pacific Shellfish Reefs in Australia, Hong Kong, and China;
  • Supporting Women Leaders in The Pacific in Papua New Guinea (Mangroves, Women, and Markets) and the Solomon Islands (Community Health and Resilience);
  • Coastal Conservation and Restoration in the Gulf Coast (Protecting the Gulf Coast Coastal Wetlands); and
  • Improving Fisheries in Mexico (Improving Fisheries and Empowering Communities).

The Nature Conservancy will launch a new global partnership to identify and protect coral reefs that are positioned to survive climate change – “Super Reefs” at the 2022 UN Ocean Conference in Lisbon, Portugal. The UN Ocean Conference, co-hosted by the Governments of Kenya and Portugal, will seek to address the threats to health, ecology, economy and governance of the ocean and propel much needed science-based innovative solutions aimed at starting a new chapter of global ocean action.

“On Earth Day, and every day, Mary Kay celebrates the work we have done to invest in our planet and protect our oceans—a resource which sustains the livelihoods of about 3 billion people worldwide. It is critical to our earth, future, and communities. Mary Kay is proud of our partnerships to help create sustainable and lasting impact in communities around the world. It is indeed a partnership for the planet,” said Deborah Gibbins, Mary Kay’s Chief Operating Officer.

“We know there is still more work to be done and we know we can, and will, do more. Taking care of our earth is important to Mary Kay and Earth Day gives us an opportunity to reaffirm our commitments to sustainable action,” added Gibbins.

To read more about Mary Kay’s commitment to sustainability, visit marykayglobal.com/sustainability and download Mary Kay’s global sustainability strategy, Enriching Lives Today for a Sustainable Tomorrow.

About The Nature Conservancy

The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world’s toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters and oceans at an unprecedented scale, providing food and water sustainably and helping make cities more sustainable. Working in 79 countries and territories, we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors of domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com , find us on Facebook , Instagram , and LinkedIn , or follow us on Twitter .

1 About the 2022 UN Ocean Conference, UN Ocean Conference Lisbon, Portugal, https://www.un.org/en/conferences/ocean2022/about

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye